These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 32760407)

  • 1. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
    Liu X; Cao W; Li T
    Front Immunol; 2020; 11():1660. PubMed ID: 32760407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
    Lin L; Lu L; Cao W; Li T
    Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
    Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
    Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.
    Gharebaghi N; Nejadrahim R; Mousavi SJ; Sadat-Ebrahimi SR; Hajizadeh R
    BMC Infect Dis; 2020 Oct; 20(1):786. PubMed ID: 33087047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.
    Fernandez-Gutierrez B
    Reumatol Clin (Engl Ed); 2020; 16(4):253-254. PubMed ID: 32345483
    [No Abstract]   [Full Text] [Related]  

  • 8. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.
    Díez JM; Romero C; Vergara-Alert J; Belló-Perez M; Rodon J; Honrubia JM; Segalés J; Sola I; Enjuanes L; Gajardo R
    Immunotherapy; 2020 Dec; 12(17):1247-1255. PubMed ID: 32900263
    [No Abstract]   [Full Text] [Related]  

  • 9. Alternative management of Covid-19 infection.
    Atrah HI
    Scott Med J; 2020 Aug; 65(3):72-75. PubMed ID: 32638647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
    Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
    Front Immunol; 2020; 11():1708. PubMed ID: 32754163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of IgG Fc receptors in antibody-dependent enhancement.
    Bournazos S; Gupta A; Ravetch JV
    Nat Rev Immunol; 2020 Oct; 20(10):633-643. PubMed ID: 32782358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
    Ali S; Shalim E; Farhan F; Anjum F; Ali A; Uddin SM; Shahab F; Haider M; Ahmed I; Ali MR; Khan S; Rao S; Guriro K; Elahi S; Ali M; Mushtaq T; Sayeed MA; Muhaymin SM; Luxmi S; Saifullah ; Qureshi S
    Trials; 2022 Nov; 23(1):932. PubMed ID: 36348476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation in COVID-19.
    Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
    Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.